Αρχική World News FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer... World News FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations Από Ogkologos - 29 Οκτωβρίου, 2024 1958 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MARIPOSA-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma 24 Αυγούστου, 2021 Virchow: The Largest Foundation Model for Computational Pathology To Date 13 Αυγούστου, 2024 A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... 12 Οκτωβρίου, 2021 Woman Who Died For 27 Minutes Shares Haunting Message When Revived 12 Αυγούστου, 2019 Φόρτωση περισσοτέρων HOT NEWS No improvement in OS, but more grade 3 or higher AEs... Spotlight On: Exercise Physiologists in Cancer Care Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... How to Clean Your Home When Caring for Someone With Cancer